Furthermore, an IL-17A-induced psoriasiform inflammation model in HaCaT keratinocytes demonstrated that XYJDY markedly suppressed AKR1B10 expression, reinforcing its candidacy as a pivotal therapeutic target in XYJDY-mediated treatment of psoriasis. Here, AKR1B10 is linked to psoriasis.